Last reviewed · How we verify
NCT06654388
To Construct a Prognosis Prediction Model for ECMO Patients Based on Machine Learning Algorithms
trial in ECMO in 290 participants. Completed in 1 October 2024.
1 October 2024
Quick facts
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 290 |
| Start date | 1 January 2018 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across China |
Conditions studied
- ECMO — all drugs for ECMO →
Sponsor
Zhujiang Hospital
Who can join
18 and older, any sex, with ECMO. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Extracorporeal membrane oxygenation (ECMO) is a critical life-support technique for patients with severe medical conditions. Various factors affect the mortality rates of patients in intensive care units, presenting a significant clinical challenge in accurately predicting outcomes based on a limited set of indicators.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06654388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ECMO
Currently open trials in the same condition.
- NCT06872021 — Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation · NA · recruiting
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT06274411 — Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention · NA · recruiting
- NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
- NCT06676085 — A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation · NA · recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
- NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
- NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
- NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06654388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06654388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing